BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ...
News Medical11h
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...
Fintel on MSN14h
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation
Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...
Beigene Unveils Proposed Name Change To Beone Medicines, Reaffirming Its Mission To Unite Global Community Against Cance...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Comp ...
Blueprint Medicines initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...